

Highlights of This Issue 5659**SPECIAL FEATURES****CCR Drug Updates****5661 FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma**

Amy Barone, Maitreyee Hazarika, Marc R. Theoret, Pallavi Mishra-Kalyani, Huanyu Chen, Kun He, Rajeshwari Sridhara, Sriram Subramaniam, Elimika Pfuma, Yanning Wang, Hongshan Li, Hong Zhao, Jeanne Fourie Zirkelbach, Patricia Keegan, and Richard Pazdur

5666 FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma

Meredith K. Chuk, Jennie T. Chang, Marc R. Theoret, Emmanuel Sampene, Kun He, Shawna L. Weis, Whitney S. Helms, Runyan Jin, Hongshan Li, Jingyu Yu, Hong Zhao, Liang Zhao, Mark Paciga, Deborah Schmiel, Rashmi Rawat, Patricia Keegan, and Richard Pazdur

CANCER THERAPY: CLINICAL**5671 Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer**

Yung-Jue Bang, Jae Yong Cho, Yeul Hong Kim, Jin Won Kim, Maria Di Bartolomeo, Jaffer A. Ajani, Kensei Yamaguchi, Agnes Balogh, Teresa Sanchez, and Markus Moehler

5679 Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I–II Melanoma: Data from Two Randomized Phase II Trials

Bas D. Koster, Mari F.C.M. van den Hout, Berbel J.R. Sluijter, Barbara G. Molenkamp, Ronald J.C.L.M. Vuylsteke, Arnold Baars, Paul A.M. van Leeuwen, Rik J. Scheper, M. Petrousjka van den Tol, Alfons J.M. van den Eertwegh, and Tanja D. de Gruijil

5687 Neratinib Efficacy and Circulating Tumor DNA Detection of *HER2* Mutations in *HER2* Nonamplified Metastatic Breast Cancer

Cynthia X. Ma, Ron Bose, Feng Gao, Rachel A. Freedman, Melinda L. Telli, Gretchen Kimmick, Eric Winer, Michael Naughton, Matthew P. Goetz, Christy Russell, Debu Tripathy, Melody Cobleigh, Andres Forero, Timothy J. Pluard, Carey Anders, Polly Ann Niravath, Shana Thomas, Jill Anderson, Caroline Bumb, Kimberly C. Banks, Richard B. Lanman, Richard Bryce, Alshad S. Lalani, John Pfeifer, Daniel F. Hayes, Mark Pegram, Kimberly Blackwell, Philippe L. Bedard, Hussam Al-Kateb, and Matthew J.C. Ellis

5696 Phase I Trial of Intravenous Oncolytic Vaccinia Virus (GL-ONC1) with Cisplatin and Radiotherapy in Patients with Locoregionally Advanced Head and Neck Carcinoma

Loren K. Mell, Kevin T. Brumund, Gregory A. Daniels, Sunil J. Advani, Kaveh Zakeri, Mary E. Wright, Sara-Jane Onyeama, Robert A. Weisman, Parag R. Sanghvi, Peter J. Martin, and Aladar A. Szalay

5703 First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor**Antibody, in Patients with Advanced Solid Tumors**

Kyriakos P. Papadopoulos, Larry Gluck, Lainie P. Martin, Anthony J. Olszanski, Anthony W. Tolcher, Gatarae Ngarmchamnanrith, Erik Rasmussen, Benny M. Amore, Dirk Nagorsen, John S. Hill, and Joe Stephenson Jr

5711 Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Jhanelle E. Gray, Rebecca S. Heist, Alexander N. Starodub, D. Ross Camidge, Ebenezer A. Kio, Gregory A. Masters, W. Thomas Purcell, Michael J. Guarino, Jamal Misleh, Charles J. Schneider, Bryan J. Schneider, Allyson Ocean, Tirrell Johnson, Leena Gandhi, Kevin Kalinsky, Ronald Scheff, Wells A. Messersmith, Serengulam V. Govindan, Pius P. Maliakal, Boyd Mudenda, William A. Wegener, Robert M. Sharkey, and David M. Goldenberg


5720 Sorafenib in Patients with Hepatocellular Carcinoma—Results of the Observational INSIGHT Study

Tom M. Ganten, Rudolf E. Stauber, Eckardt Schott, Peter Malfertheiner, Robert Buder, Peter R. Galle, Thomas Göhler, Matthias Walther, Ronald Koschny, and Guido Gerken



Table of Contents


PERSONALIZED MEDICINE AND IMAGING

- 5729** **Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy**
Yulian Khagi, Aaron M. Goodman, Gregory A. Daniels, Sandip P. Patel, Assuntina G. Sacco, James M. Randall, Lyudmila A. Bazhenova, and Razelle Kurzrock
- 5737** **Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome**
Mizuki Nishino, Suzanne E. Dahlberg, Anika E. Adeni, Christine A. Lydon, Hiroto Hatabu, Pasi A. Jänne, F. Stephen Hodi, and Mark M. Awad
- 5745** **Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials**
Benjamin M. Ellingson, Elizabeth R. Gerstner, Marion Smits, Raymond Y. Huang, Rivka Colen, Lauren E. Abrey, Dana T. Aftab, Gisela M. Schwab, Colin Hessel, Robert J. Harris, Ararat Chakhoyan, Renske Gahrman, Whitney B. Pope, Kevin Leu, Catalina Raymond, Davis C. Woodworth, John de Groot, Patrick Y. Wen, Tracy T. Batchelor, Martin J. van den Bent, and Timothy F. Cloughesy
- 5757** **Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer**
M. Eileen Dolan, Omar El Charif, Heather E. Wheeler, Eric R. Gamazon, Shirin Ardeshtir-Rouhani-Fard, Patrick Monahan, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Chunkit Fung, Jeri Kim, Sophie D. Fossa, Daniel L. Hertz, Taisei Mushiroda, Michiaki Kubo, Lawrence H. Einhorn, Nancy J. Cox, and Lois B. Travis; for the Platinum Study Group
- 5769** **Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: Multimodal Functional Imaging and Multiplex Cytokine Analysis**
 Shigeto Ueda, Toshiaki Saeki, Akihiko Osaki, Tomohiko Yamane, and Ichiei Kuji
- 5779** **PD-1⁺ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer**
Marco Donia, Julie Westerlin Kjeldsen, Rikke Andersen, Marie Christine Wulff Westergaard, Valentina Bianchi, Mateusz Legut, Meriem Attaf, Barbara Szomolay, Sascha Ott, Garry Dolton, Rikke Lyngaa, Sine Reker Hadrup, Andrew K. Sewell, and Inge Marie Svane

CANCER THERAPY: PRECLINICAL

- 5789** **Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice**
Elizabeth Ahern, Heidi Harjunpää, Deborah Barkauskas, Stacey Allen, Kazuyoshi Takeda, Hideo Yagita, David Wyld, William C. Dougall, Michele W.L. Teng, and Mark J. Smyth
- 5802** **Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models**
Michelle L. Cook Sangar, Laura A. Genovesi, Madison W. Nakamoto, Melissa J. Davis, Sue E. Knobluagh, Pengxiang Ji, Amanda Millar, Brandon J. Wainwright, and James M. Olson
- 5814** **Combined BTK and PI3K δ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model**
Carsten U. Niemann, Helena I. Mora-Jensen, Eman L. Dadashian, Fanny Krantz, Todd Covey, Shih-Shih Chen, Nicholas Chiorazzi, Raquel Izumi, Roger Ulrich, Brian J. Lannutti, Adrian Wiestner, and Sarah E.M. Herman
- 5824** **Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells**
Lucía Fernández, Jean-Yves Metais, Adela Escudero, María Vela, Jaime Valentín, Isabel Vallcorba, Alejandra Leivas, Juan Torres, Antonio Valeri, Ana Patiño-García, Joaquín Martínez, Wing Leung, and Antonio Pérez-Martínez
- 5836** **SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression**
Gulden Menderes, Elena Bonazzoli, Stefania Bellone, Jonathan Black, Federica Predolini, Francesca Pettinella, Alice Masserdotti, Luca Zammataro, Gary Altwerger, Natalia Buza, Pei Hui, Serena Wong, Babak Litkouhi, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Peter E. Schwartz, and Alessandro D. Santin
- 5846** **Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus**
Emma Eriksson, Ioanna Milenova, Jessica Wenche, Magnus Ståhle, Justyna Leja-Jarblad, Gustav Ullenhag, Anna Dimberg, Raphael Moreno, Ramon Alemany, and Angelica Loskog

Table of Contents

- 5858** Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates
Mary Jane Masson Hinrichs, Pauline M. Ryan, Bo Zheng, Shameen Afif-Rider, Xiang Qing Yu, Michele Gunsior, Haihong Zhong, Jay Harper, Binyam Bezabeh, Kapil Vashisht, Marlon Rebelatto, Molly Reed, Patricia C. Ryan, Shannon Breen, Neki Patel, Cui Chen, Luke Masterson, Arnaud Tiberghien, Phillip W. Howard, Nazzareno Dimasi, and Rakesh Dixit
- 5869**  Combination Therapy with NHS-muLL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models
Chunxiao Xu, Yanping Zhang, P. Alexander Rolfe, Vivian M. Hernández, Wilson Guzman, Giorgio Kradjian, Bo Marelli, Guozhong Qin, Jin Qi, Hong Wang, Huakui Yu, Robert Tighe, Kin-Ming Lo, Jessie M. English, Laszlo Radvanyi, and Yan Lan
- 5881** MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer
Venugopal Gunda, Joshua Soucek, Jaime Abrego, Surendra K. Shukla, Gennifer D. Goode, Enza Vernucci, Aneesha Dasgupta, Nina V. Chaika, Ryan J. King, Sicong Li, Shuo Wang, Fang Yu, Tadayoshi Bessho, Chi Lin, and Pankaj K. Singh
- 5892** Downregulation of Human Endogenous Retrovirus Type K (HERV-K) Viral *env* RNA in Pancreatic Cancer Cells Decreases Cell Proliferation and Tumor Growth
Ming Li, Laszlo Radvanyi, Bingnan Yin, Jia Li, Raghavender Chivukula, Kevin Lin, Yue Lu, JianJun Shen, David Z. Chang, Donghui Li, Gary L. Johanning, and Feng Wang-Johanning
- 5912** Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer
Wei-Lei Yang, Aleksandra Gentry-Maharaj, Archana Simmons, Andy Ryan, Evangelia Ourania Fourkala, Zhen Lu, Keith A. Baggerly, Yang Zhao, Karen H. Lu, David Bowtell, for the AOCS Study Group, Ian Jacobs, Steven J. Skates, Wei-Wu He, Usha Menon, and Robert C. Bast Jr
- 5923** Sym015: A Highly Efficacious Antibody Mixture against *MET*-Amplified Tumors
Thomas Tuxen Poulsen, Michael Monrad Grandal, Niels Jørgen Østergaard Skartved, Rikke Hald, Lene Alifrangis, Klaus Koefoed, Trine Lindsted, Camilla Fröhlich, Sofie Ellebæk Pollmann, Karsten Wessel Eriksen, Anna Dahlman, Helle Jane Jacobsen, Thomas Bouquin, Mikkel Wandahl Pedersen, Ivan David Horak, Johan Lantto, and Michael Kragh

BIOLOGY OF HUMAN TUMORS


- 5936** Mutational Heterogeneity in *APC* and *KRAS* Arises at the Crypt Level and Leads to Polyclonality in Early Colorectal Tumorigenesis
Mireia Gausachs, Ester Borrás, Kyle Chang, Sara Gonzalez, Daniel Azuara, Axel Delgado Amador, Adriana Lopez-Doriga, F. Anthony San Lucas, Xavier Sanjuan, Maria J. Paules, Melissa W. Taggart, Gareth E. Davies, Erik A. Ehli, Jerry Fowler, Victor Moreno, Marta Pineda, Y. Nancy You, Patrick M. Lynch, Conxi Lazaro, Nicholas E. Navin, Paul A. Scheet, Ernest T. Hawk, Gabriel Capella, and Eduardo Vilar
- 5948**  Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy
Daniel L. Adams, Diane K. Adams, Jianzhong He, Neda Kalhor, Ming Zhang, Ting Xu, Hui Gao, James M. Reuben, Yawei Qiao, Ritsuko Komaki, Zhongxing Liao, Martin J. Edelman, Cha-Mei Tang, and Steven H. Lin
- 5959** Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma
Hao Liu, Kamila Naxerova, Matthias Pinter, Joao Incio, Hang Lee, Kohei Shigeta, William W. Ho, Jonathan A. Crain, Alex Jacobson, Theodoros Michelakos, Daniella Dias-Santos, Andrea Zanonato, Theodore S. Hong, Jeffrey W. Clark, Janet E. Murphy, David P. Ryan, Vikram Deshpande, Keith D. Lillemoe, Carlos Fernandez-del Castillo, Michael Downes, Ronald M. Evans, James Michaelson, Cristina R. Ferrone, Yves Boucher, and Rakesh K. Jain
- 5970** Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of *MED12* and *RBM10* as Novel Thyroid Cancer Genes Associated with Tumor Virulence
Tihana Ibrahimasic, Bin Xu, Iñigo Landa, Snjezana Dogan, Sumit Middha, Venkatraman Seshan, Shyam Deraje, Diane L. Carlson, Jocelyn Migliacci, Jeffrey A. Knauf, Brian Untch, Michael F. Berger, Luc Morris, R. Michael Tuttle, Timothy Chan, James A. Fagin, Ronald Ghossein, and Ian Ganly



Table of Contents

- 5981** A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors
-  Joaquin Mateo, Gopinath Ganji, Charlotte Lemech, Howard A. Burris, Sae-Won Han, Karen Swales, Shaun Decordova, M. Phillip DeYoung, Deborah A. Smith, Shanker Kalyana-Sundaram, Jiuhua Wu, Monica Motwani, Rakesh Kumar, Jerry M. Tolson, Sun Young Rha, Hyun Cheol Chung, Joseph P. Eder, Sunil Sharma, Yung-Jue Bang, Jeffrey R. Infante, Li Yan, Johann S. de Bono, and Hendrik-Tobias Arkenau


- 5994** FDA Approval Summary: Sonidegib—Response
- Stacy S. Shord, Denise Casey, Hong Zhao, Suzanne Demko, Patricia Keegan, and Richard Pazdur

CORRECTION

- 5995** Correction: T-cell Receptor Signaling Activates an ITK/NF- κ B/GATA-3 Axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy

LETTER TO THE EDITOR

- 5993** FDA Approval Summary: Sonidegib—Letter
- Bishal Gyawali and Yuichi Ando

 AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a section of a pediatric patient-derived group 3 medulloblastoma tumor that regressed following treatment with a CDK4/6 inhibitor called palbociclib (Ibrance, Pfizer, Inc.). Histologic analysis revealed that the drug caused a significant change in the morphology of the tumor cells, including cytomegaly, vacuolated chromatin, and prominent nucleoli. For details, see the article by Cook Sangar and colleagues on page 5802 of this issue.

